An observational study investigating and auditing the safety, tolerability and further efficacy characteristics of a pharmaceutical grade cannabis medicine (NanaBis™) prescribed to eligible patients for the management of cancer related or non-cancer related pain in general and specialty medical practices.

Medlab Clinical0 个研究点目标入组 2,000 人开始时间: 2019年4月1日最近更新: 2022年8月22日

适应症

试验速览

暂无简介。

•1.Prospective participants greater than or equal to 18 years of age at time of entry on study;
•2.Prospective participants have the cognitive ability to understand the informed consent process and to give informed consent to participate in the observational study;
•3.Prospective participants have been lawfully prescribed NanaBis™ by their Consenting Doctor;
•4.Prospective participants are prescribed NanaBis™ for the management of cancer related or non-cancer related pain;
•5.Prospective participants are able to visit the Consenting Doctor as required while administering NanaBis™ and are able to provide information as required to the Consenting Doctor for the duration of the study;
•6.Prospective participants agree to abstain from using cannabis products other than NanaBis™ for the duration of their participation in the study.

•1.Prospective participants will be ineligible if they are under the age of 18 years;
•2.Prospective participants will be ineligible if they are unwilling or unable to sign the Informed Consent Form or cannot understand the Participant Information Sheet provided;
•3.Prospective participants will be ineligible if the Consenting Doctor determines that the prospective participant is unable to fulfill any of the requirements of the study;
•4.Prospective participants will be ineligible if they are unwilling or unable to perform study procedures as described in the study protocol.
•5. Prospective participants will be ineligible if they are currently using Illicit drugs and/or with alcohol abuse.

发起方

Medlab Clinical